Get the Stockscreener App
1.34
10.67%
-0.16
After Hours:
1.36
0.02
+1.49%
Reviva Pharmaceuticals Holdings Inc stock is traded at $1.34, with a volume of 4.44M.
It is down -10.67% in the last 24 hours and up +10.29% over the past month.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
See More
Previous Close:
$1.50
Open:
$1.5
24h Volume:
4.44M
Relative Volume:
2.61
Market Cap:
$60.89M
Revenue:
-
Net Income/Loss:
$-37.65M
P/E Ratio:
-0.9504
EPS:
-1.41
Net Cash Flow:
$-24.14M
1W Performance:
-48.66%
1M Performance:
+10.29%
6M Performance:
-0.74%
1Y Performance:
-63.49%
1-Day Range:
$1.23
$1.51
1-Week Range:
$1.23
$2.74
52-Week Range:
$0.60
$5.67
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Name
Reviva Pharmaceuticals Holdings Inc
Sector
Industry
Phone
(408) 501-8881
Address
10080 N WOLFE ROAD, CUPERTINO
Compare RVPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
1.34 | 60.89M | 0 | -37.65M | -24.14M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-23 | Initiated | ROTH MKM | Buy |
| Jun-08-23 | Initiated | The Benchmark Company | Speculative Buy |
| Jan-24-22 | Initiated | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World
Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering - MarketWatch
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Reviva Pharmaceuticals Announces $18M Public Offering with Warrant Package to Fund R&D Pipeline - StockTitan
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants - GlobeNewswire
Reviva Announces Proposed Public Offering - GlobeNewswire
Reviva Pharmaceuticals Launches Public Offering to Fund CNS Drug Development Pipeline - StockTitan
Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results - TipRanks
Reviva Announces Positive Preliminary Topline Data for the - GlobeNewswire
Reviva's Brilaroxazine Shows Promising Long-Term Results in Phase 3 Schizophrenia Trial - StockTitan
Reviva Pharmaceuticals Holdings, Inc. Holds Annual Meeting and Approves Increase in Authorized Shares - Defense World
Largest borrow rate increases among liquid names - TipRanks
Reviva Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low - Seeking Alpha
Analyzing Reviva Pharmaceuticals (NASDAQ:RVPH) and Akebia Therapeutics (NASDAQ:AKBA) - Defense World
RVPH: Year-End OLE Update - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Reviva Pharmaceuticals Holdings Inc - GuruFocus.com
Schonfeld Strategic Advisors LLC Increases Stake in Reviva Pharm - GuruFocus.com
Reviva Pharmaceuticals Holdings Inc. Warrants (RVPHW) Quarterly 10-Q Report - Quartzy
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Reviva Pharma: 108 Patients Complete 1-Year Schizophrenia Drug Trial as Losses Narrow | RVPH Stock News - StockTitan
Reviva reports progress in schizophrenia treatment study By Investing.com - Investing.com Australia
Reviva reports progress in schizophrenia treatment study - Investing.com
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - GlobeNewswire
Reviva's Brilaroxazine Hits Key Milestone: 108 Patients Complete 1-Year Schizophrenia Trial | RVPH Stock News - StockTitan
Reviva to Present Positive Speech Latency Data for - GlobeNewswire
Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit | RVPH Stock News - StockTitan
Reviva to Participate in the UBS Global Healthcare Conference - GlobeNewswire
Reviva To Report Long-Term Safety Data For Brilaroxazine In Schizophrenia: Will The Stock Recover? - RTTNews
Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst - Benzinga
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference - The Manila Times
CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment - Streetwise Reports
RVPH’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Market Momentum: Reviva Pharmaceuticals Holdings Inc. (RVPH) Registers a 9.40 Increase, Closing at 1.28 - The Dwinnex
RVPH: RECOVER Biomarker KOL Event - Yahoo Finance
Closing Strong: Reviva Pharmaceuticals Holdings Inc. (RVPH) Ends at 1.12, Down -13.85 from Last Close - The Dwinnex
A stock that deserves closer examination: Reviva Pharmaceuticals Holdings Inc. (RVPH) - US Post News
Reviva reports positive schizophrenia trial results - Investing.com India
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - GlobeNewswire
How to interpret Reviva Pharmaceuticals Holdings Inc. (RVPH)’s stock chart patterns - US Post News
Reviva Pharmaceuticals Holdings Inc. (RVPH) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):